ArticleOncology research2026

Targeting Dynamin-Related Protein 1 and Glucose Metabolism Reverses Acquired Resistance to Sorafenib in Liver Cancer.

Jinhui Che et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.